Oral Vancomycin for Preventing Clostridium Difficile Recurrence
Status:
Terminated
Trial end date:
2021-04-22
Target enrollment:
Participant gender:
Summary
This study evaluates the role of oral vancomycin in the prevention of recurrent Clostridium
difficile for hospitalized patients receiving systemic antibiotic therapy. Half of
participants will receive oral vancomycin daily, while the other half will receive a placebo.